COVID-19 Pfizer Information
Investigator Information and How to Contact Us
Business Development
Pfizer's Sponsored Scientific Presentations including Abstract Plain Language Summaries
Get it Done: Return to Cancer Screening Telehealth Guide for Patients - English Version
Get It Done: Return to Cancer Screening Telehealth Guide for Patients - Spanish Version
Get It Done: Return to Cancer Screening In-Person Guide for Patients – English Version
Get It Done: Return to Cancer Screening In-Person Guide for Patients – Spanish Version
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
What to Expect With Your Cancer Care During COVID-19
What to Expect With Your Cancer Care During COVID-19 – Spanish Version
Clinical Trial Resources
Connect with Talent Acquisition
ABC Global Alliance
Hard-to-Reach ABC/mBC Communities Toolkit
Global Medical Grants Oncology Brochure
PROTEUS Consortium (Patient-Reported Outcomes Tools: Engaging Users & Stakeholders) and Pfizer GMG QI RFP
NCCN-Myovant Sciences-Pfizer Alliance: Understanding and Mitigating CV Risk in Pts with PC, QI RFP
Age: Addressing a Blind Spot in Cancer Care
Some Older People Living with Cancer Aim for Remission but Lack Needed Resources to Help Make Treatment Decisions
Improving Access to Care for Underserved Patient Populations
Digitally Empowered (a collaboration between Patient Empowerment Network and Pfizer)
The Role of Cyclin-Dependent Kinases (CDK) 2/4/6 in Normal and Tumor Cells
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
Discover the Oncology Development Program and Clinical Trials
Pfizer Medical Information
Learn About Our Oncology Approved Medicines
Pfizer's Sponsored Scientifc Presentations including Abstract Plain Language Summaries
Spotlight Theater Invite
Lung Narrative
Hematologic Malignancies
Genitourinary Cancers
Colorectal Cancers Melanoma
Biosimilars
This is Living with Cancer
Pfizer Oncology Together
Abstract Plain Language Summaries
Breast Cancer Vision
Spotlight Theater
Follow Us
Find My U.S.
Thanks for finding us at AACR 2022
Who We Are and What We Do
One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases
Thank you for finding us at AACR 2022
Who We Are and What We Do
One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases
Upcoming Opportunities to Connect
Oral Presentations
Spotlight Theater
A new ASTRO-Pfizer-Myovant New Combination (Relugolix-Radiation) Therapy Challenge for ISR will be released soon. Please go to http://www.pfizer.com/ISR to sign up for alerts or to view ASTRO’s Program Announcement online visit: https://www.astro.org/Patient-Care-and-Research/Research/Scientific-Challenges
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
